According to Roche, the HER2 (4B5) clone consistently achieves high proficiency assessment scores against other clones. "FDA ...

Rabbit Monoclonal Primary Antibody test as a companion diagnostic to assess HER2+ status in patients with BTC.

The FDA has approved a new drug, zanidatamab, for adults with advanced biliary tract cancer, or BTC. Marketed under the brand ...

Zanidatamab is the first agent approved specifically for advanced, HER2-positive second-line biliary tract cancer.

Roche (RHHBY) announced that the U.S. Food and Drug Administration has approved an expansion of the PATHWAY anti-HER2/neu (4B5) ...

US FDA approves Roche’s companion diagnostic to identify patients with biliary tract cancer eligible for HER2-targeted treatment with Ziihera: Tucson, Arizona Tuesday, November ...

The mutation causes the gene to produce too many HER2/neu proteins (or just HER2 proteins). In normal amounts, these proteins act as receptors that tell the breast cells how much to grow (and when ...

and human epidermal growth factor receptor 2 (HER2/neu)—that targeted medications act upon to reduce tumor growth. Most breast cancers, especially when detected early, are treated successfully ...

MARGENZA is a HER2/neu receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or ...

The universal cell-cycle inhibitor p21 Cip1/WAF1 is phosphorylated and localized in the cytoplasm in Her2/neu-overexpressing breast cancers as a result of its physical association with the ...